What is the expected revenue for the company in 10 years from the thematic indexes, ETFs, and mutual funds
ndexes. But what you will start to see is maybe some of the bigger ones, a BlackRock or Amundi or others, they might create an ETF. If we launch an oncology index, an oncology ETF or we launch an early stage biotech index, maybe an early stage biotech ETF and then mutual funds. So it will take time.
And I even think that the revenue next year is going to probably be very small because, again, it's all in the launch phase. But at some point, this will gain momentum. And if you just look at the fact that today there's $400 billion invested in these thematic indexes, $100 billion in ETFs and $300 billion in mutual funds, and a lot of that is technology because there's really -- life sciences is behind. It hasn't really happened.
So could that $400 billion grow over the next 10 years to $1 trillion? I think it will, probably. And what share of that is going to be life sciences? And so then you have to go through the economics that MSCI will get and then what we will get. So I think this is something that looking in sort of the second half of this decade could become important. But maybe as time evolves and we get a better sense of how this could grow, we could be a little bit more specific.
At this stage, I am very excited because it not only shows then that what we can do with the Royalty Pharma models -- and things that were totally unexpected. I mean nobody thought of this, had it in their model. So it's potentially something new for us. And it also will benefit -- I mean, there was a question before about whether this will benefit our core business.
And absolutely, it will. Why? Because in that effort of us really looking into life sciences and trying to look in on 3, 5 years as to what are you -- what's going to be the important therapeutic areas and we'll also start to look at the companies that are starting to invest in that, many of which may have things in preclinical. But if you start to look at those companies and track them through an index and you start to see how this value creation begins or how capital is shifting from -- into those areas, it will give us a feel for that. And just as an illustration.
I mean things that -- a Chinese biotech, for example. We looked at it last fall as we were starting to talk to MSCI about this. And I was blown away to realize, we -- myself and the team have been going to China in the past years to try to explore if there's anything for us to do in that market. I was just blown away last fall when I checked the market cap of Chinese biotech, and it was about $700 billion and I think that it went to those guys, maybe $1 trillion.
And there's about 800 Chinese biotech companies that are public, 800 biotech companies, which is a very significant number. So it gives you a sense of what's going on in other markets, and it will help us at Royalty Pharma to also make sure that we're really understanding the space in a very deep way and we can understand the trends better. So that's additional perspective that I wanted to provide.
Terry Coyne -- Executive Vice President, Chief Financial Officer
And then, Dave, on your question on the cystic fibrosis franchise, we've certainly heard comments for Vertex about future potential combinations and potential lower royalty rates on those combos, and our position's unchanged. So as it relates to any combination that includes deuterated Kalydeco, our position is that deuterated Kalydeco is simply Kalydeco and Kalydeco is a collaboration compound that's royalty-bearing. And with regard to any other components of combination products, I think there's a number of factors to consider. So which components are they? And are they royalty-bearing and at what level? And then as those combos move forward, it's time to enroll the clinical trials in a population that is, at this point, pretty well served.
And then our success and timing of potential regulatory approvals and then ultimate uptake versus Trikafta, which is a pretty remarkable drug for CF patients. So our view is that we expect the CF to be a very important contributor to our business for many ye
ndexes. But what you will start to see is maybe some of the bigger ones, a BlackRock or Amundi or others, they might create an ETF. If we launch an oncology index, an oncology ETF or we launch an early stage biotech index, maybe an early stage biotech ETF and then mutual funds. So it will take time.
And I even think that the revenue next year is going to probably be very small because, again, it's all in the launch phase. But at some point, this will gain momentum. And if you just look at the fact that today there's $400 billion invested in these thematic indexes, $100 billion in ETFs and $300 billion in mutual funds, and a lot of that is technology because there's really -- life sciences is behind. It hasn't really happened.
So could that $400 billion grow over the next 10 years to $1 trillion? I think it will, probably. And what share of that is going to be life sciences? And so then you have to go through the economics that MSCI will get and then what we will get. So I think this is something that looking in sort of the second half of this decade could become important. But maybe as time evolves and we get a better sense of how this could grow, we could be a little bit more specific.
At this stage, I am very excited because it not only shows then that what we can do with the Royalty Pharma models -- and things that were totally unexpected. I mean nobody thought of this, had it in their model. So it's potentially something new for us. And it also will benefit -- I mean, there was a question before about whether this will benefit our core business.
And absolutely, it will. Why? Because in that effort of us really looking into life sciences and trying to look in on 3, 5 years as to what are you -- what's going to be the important therapeutic areas and we'll also start to look at the companies that are starting to invest in that, many of which may have things in preclinical. But if you start to look at those companies and track them through an index and you start to see how this value creation begins or how capital is shifting from -- into those areas, it will give us a feel for that. And just as an illustration.
 I mean things that -- a Chinese biotech, for example. We looked at it last fall as we were starting to talk to MSCI about this. And I was blown away to realize, we -- myself and the team have been going to China in the past years to try to explore if there's anything for us to do in that market. I was just blown away last fall when I checked the market cap of Chinese biotech, and it was about $700 billion and I think that it went to those guys, maybe $1 trillion.
And there's about 800 Chinese biotech companies that are public, 800 biotech companies, which is a very significant number. So it gives you a sense of what's going on in other markets, and it will help us at Royalty Pharma to also make sure that we're really understanding the space in a very deep way and we can understand the trends better. So that's additional perspective that I wanted to provide.
Terry Coyne -- Executive Vice President, Chief Financial Officer
And then, Dave, on your question on the cystic fibrosis franchise, we've certainly heard comments for Vertex about future potential combinations and potential lower royalty rates on those combos, and our position's unchanged. So as it relates to any combination that includes deuterated Kalydeco, our position is that deuterated Kalydeco is simply Kalydeco and Kalydeco is a collaboration compound that's royalty-bearing. And with regard to any other components of combination products, I think there's a number of factors to consider. So which components are they? And are they royalty-bearing and at what level? And then as those combos move forward, it's time to enroll the clinical trials in a population that is, at this point, pretty well served.
And then our success and timing of potential regulatory approvals and then ultimate uptake versus Trikafta, which is a pretty remarkable drug for CF patients. So our view is that we expect the CF to be a very important contributor to our business for many ye